In a welcome move, Stryker saw its Relative Strength Rating improve from 63 to 71 on Thursday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating of at least 80 as they launch their largest runs. See if Stryker can continue to rebound and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Stryker is working on a consolidation with a 281.26 buy point. See if the stock can clear the breakout price in heavy trading.
Stryker showed -4% EPS growth in its most recent report, while sales growth came in at 10%.
Stryker holds the No. 12 rank among its peers in the Medical-Products industry group. Baxter International and Boston Scientific are also among the group's highest-rated stocks.
